Skip to main content
padlock icon - secure page this page is secure

Revising Skin Cancers by Means of Epigenetic Markers

Buy Article:

$68.00 + tax (Refund Policy)

Skin neoplasms represent a group of cutaneous disorders comprising primarily basal cell carcinoma, cutaneous squamous cell carcinoma, malignant melanoma and cutaneous lymphoma. Until the last few years, not all skin cancers subtypes have been studied in an epigenetic milieu. Among skin cancer subtypes, melanoma is the most discussed from the epigenetic point of view due to its aggressiveness and its proven resistance to radiotherapy procedures. Epigenetic deregulations comprise reversible modifications of the nuclear material, for instance aberrant methylation of DNA, posttranslational modifications of histones and recently considered, microRNAs profiles. A relevant number of patents and clinical trials regarding the use of epigenetic drugs alone or in combination with classical procedures have been developed especially for melanoma treatment. Due to their particular aggressive character, cutaneous lymphomas or even the rare Merkel cell carcinoma has been started to be intensively investigated upon epigenetic context, leading also to develop new therapy options and novel patents for their treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cutaneous lymphomas; Epigenetic drugs; Merkel cell carcinoma; Squamous cell carcinoma; clinical trials; lymphoma; melanoma; patents; skin cancers; tumorigenesis

Document Type: Research Article

Publication date: May 1, 2012

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more